A5056286543- Neuroblastoma Research and Treatments
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Protein Degradation and Inhibitors
- PARP inhibition in cancer therapy
- Microbial Natural Products and Biosynthesis
- Peptidase Inhibition and Analysis
- Cancer, Hypoxia, and Metabolism
- Synthetic Organic Chemistry Methods
- Breast Cancer Treatment Studies
- Protein Tyrosine Phosphatases
- Infectious Diseases and Mycology
- Biochemical and Molecular Research
- Protist diversity and phylogeny
- Marine Sponges and Natural Products
- Lung Cancer Treatments and Mutations
- Liver physiology and pathology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Treatment and Pharmacology
- Genetic Associations and Epidemiology
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Pediatric Hepatobiliary Diseases and Treatments
Illumina (United States)
2023-2025
Foundation Medicine (United States)
2021-2023
Editas Medicine (United States)
2022
Genomic Health (United States)
2018
NSABP Foundation
2013
Discovery Institute
2008-2009
University of Pittsburgh
2007-2009
The most useful biomarkers for clinical decision-making identify patients likely to have improved outcomes with one treatment vs another.To evaluate class-specific of receiving immune checkpoint inhibitor (ICI) taxane chemotherapy by tumor mutational burden (TMB).This comparative effectiveness analysis variables and used prospectively defined biomarker-stratified genomic data from a deidentified clinicogenomic database. Data included men previously treated metastatic castration-resistant...
Neuroblastoma evolution, heterogeneity, and resistance remain inadequately defined, suggesting a role for circulating tumor DNA (ctDNA) sequencing. To define the utility of ctDNA profiling in neuroblastoma, 167 blood samples from 48 high-risk patients were evaluated using comprehensive genomic profiling. At least one pathogenic alteration was identified 56% 73% evaluable patients, including clinically actionable ALK RAS-MAPK pathway variants. Fifteen received inhibition (ALKi), data revealed...
85 Background: Testing for HRRm is standard of care all mCRPC patients to identify those eligible receive PARPi targeted therapy. Our previous real-world analysis testing and treatment patterns (1/1/2020 – 12/31/2021) revealed 40.8% did not while 33.2% positive (HRRm+) a PARPi. The approval novel hormonal therapies (NHT) in combination with first line prompted us expand our analysis, determine timing relation therapy (LOT) initiated, LOT when NHT and/or were received, breakdown HRRm+ genes...
Liquid biopsy is a powerful tool that can enable treatment decisions for metastatic prostate cancer patients with difficult-to-biopsy tumors. However, the detection of genomic alterations via liquid limited by fraction (tumor [TF]) circulating tumor DNA (ctDNA) within total cell-free content. While prior work has preliminarily correlated TF clinical features cancer, we sought to validate and provide additional resolution, such practitioner might anticipate probability successful profiling...
The University of Pittsburgh Molecular Library Screening Center (Pittsburgh, PA) conducted a screen with the National Institutes Health compound library for inhibitors in vitro cell division cycle 25 protein (Cdc25) B activity during pilot phase Network. Seventy-nine (0.12%) 65,239 compounds screened at 10 μM met active criterion ≥50% inhibition Cdc25B activity, and (31.6%) these were confirmed as 50% inhibitory concentration (IC50) values <50 μM. Thirteen represented by singleton chemical...
Disorazoles comprise a family of 29 macrocyclic polyketides isolated from the fermentation broth myxobacterium <i>Sorangium cellulosum</i>. The major product, disorazole A<sub>1</sub>, was found previously to irreversibly bind tubulin and have potent cytotoxic activity against tumor cells, possibly because its highly electrophilic epoxide moiety. To test this hypothesis, we synthesized epoxide-free C<sub>1</sub> it retained antiproliferative causing prominent G<sub>2</sub>/M phase arrest...
210 Background: Routine germline and somatic testing is recommended by professional guidelines as standard of care for all mCRPC patients since the approvals poly ADP ribose polymerase inhibitors (PARPi) treatment in those with tumors harboring select HRRm. Yet, analyses suggest that many are not offered thus HRRm+ may have shared decision-making opportunity to consider PARPi therapy. We reviewed HRR patterns within a real-world cohort identify potential clinical practice gaps. Methods: The...
3051 Background: Clonal hematopoiesis (CH), characterized by the presence of somatic mutations in blood cells, can be found cancer-related genes when sequencing tumor tissue or plasma samples. Inability to distinguish somatic, tumor-derived from CHm lead inaccurate treatment decisions. In this prospective study, we confirmed potential solid tumors and analysis paired matched normal (PMN) specimens. Methods: We prospectively enrolled 56 patients diagnosed with advanced cancer, including lung...
Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at time. Unlike traditional single tests, comprehensive genomic profiling (CGP) can simultaneously assess NSCLC tumors hundreds of biomarkers markers response, leading quicker more precise matches therapeutics.
Liquid biopsy is a valuable tool in advanced and metastatic cancers for detection of genomic alterations tumors that facilitate personalized targeted therapy approaches. Analyzing circulating tumor DNA (ctDNA) using next-generation sequencing (NGS) provides an opportunity to detect changes during capture inter- intra-heterogeneity genomically divergent cancer cell evolution. Herein, we present patient with castration-resistant prostate cancer, progression soft tissues, bone, regional lymph...
<div>Abstract<p>Neuroblastoma evolution, heterogeneity, and resistance remain inadequately defined, suggesting a role for circulating tumor DNA (ctDNA) sequencing. To define the utility of ctDNA profiling in neuroblastoma, 167 blood samples from 48 high-risk patients were evaluated using comprehensive genomic profiling. At least one pathogenic alteration was identified 56% 73% evaluable patients, including clinically actionable <i>ALK</i> RAS–MAPK pathway variants....
Supplementary Data from Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma
Supplementary Data from Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma
<div>Abstract<p>Neuroblastoma evolution, heterogeneity, and resistance remain inadequately defined, suggesting a role for circulating tumor DNA (ctDNA) sequencing. To define the utility of ctDNA profiling in neuroblastoma, 167 blood samples from 48 high-risk patients were evaluated using comprehensive genomic profiling. At least one pathogenic alteration was identified 56% 73% evaluable patients, including clinically actionable <i>ALK</i> RAS–MAPK pathway variants....
Supplementary Data from Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma
Supplementary Data from Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma
e17053 Background: Approval of the PARPi in May 2020 caused a paradigm shift treatment mCRPC patients with homologous recombination repair (HRR) mutations. Gaps remain optimal prescribing eligible patients, negative consequences on clinical outcomes. The goal this study was to look at practices HRR mutations overall and by sub-mutation. Methods: Integra Connect PQ-deidentified real-world database used, comprising over 1 million cancer across 275 sites care, which 80% were community 20%...
Cellular senescence is a permanent state of cell cycle arrest that prevents proliferation but allows the cells to be metabolically active. Premature cellular stimulated by variety extracellular and intracellular stimuli including oxidative damage, supraphysiological mitogenic signaling, transforming growth factor‐β, retinoids, oncogenes, DNA damage some cancer chemotherapeutic agents. Disorazoles are macrocyclic polyketides isolated from fermentation broth myxobacterium Sorangium cellulosum...
Abstract Background: Pembrolizumab recently received pan-tumor FDA approval for the treatment of patients with unresectable or metastatic solid tumors tumor mutational burden (TMB) &gt;10 mutations per megabase (mut/Mb) and who have no satisfactory alternative options. The KEYNOTE-119 TAPUR trials validated TMB as a predictive biomarker using cutoffs ≥ 10 mut/Mb 9 mut/Mb, respectively, benefit from single-agent pembrolizumab in subsets clinically advanced breast cancer (aBC). Limited...